Reviewer's report

Title: Relapsing MAP-Kinase Inhibitor-Induced Pneumonitis, a case report.

Version: 2  Date: 24 March 2015

Reviewer: Ryan Sullivan

Reviewer's report:

This is a well written and important report of a 50 yo man with metastatic, BRAF-mutant melanoma who developed pneumonitis in the setting of trametinib and then again with the commencement of vemurafenib. I believe this report would be a valuable addition to the medical literature (Boardering between an article of importance in its field and an article whose findings are important to those with closely related research interests) about MAPK inhibitors and support its acceptance for publication with only minor essential revisions. In fact, the only two specific comments are:

1) The first sentence of the abstract reads currently: ³BRAF and MEK inhibitors which are effectors of the MAP kinase pathway�. While BRAF and MEK are rightly to be considered effectors of the MAP kinase pathway, inhibitors of these proteins are not. This sentence must be rewritten.

2) The authors should be sure to ³spell out² an abbreviation the first time it is used. Examples include MAP (in reference to the MAP kinase), HRCT, and PCR.

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have no conflicts of interest.